Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

被引：0

作者：

Nadeem, Omar ^{[1
]}

Redd, Robert ^{[1
]}

Mo, Clifton ^{[1
]}

Laubach, Jacob ^{[1
]}

Richardson, Paul G. ^{[1
]}

Prescott, Julia ^{[1
]}

Marto, Marjorie ^{[1
]}

Davie, Christine ^{[1
]}

Ricciardi, Caroline ^{[1
]}

Murphy, Elizabeth ^{[1
]}

Bertoni, Meredith ^{[1
]}

Choden, Dechen ^{[1
]}

Magidson, Sophie ^{[1
]}

Sheehan, Brian ^{[1
]}

Shrestha, Hira ^{[1
]}

Sperling, Adam S. ^{[1
]}

O'Donnell, Elizabeth K. ^{[2
]}

Ghobrial, Irene M. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-099

引用

页码：S89 / S89

页数：1

共 50 条

[1] Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Nadeem, Omar
Magidson, Sophie
Redd, Robert A.
Laubach, Jacob
Mo, Clifton C.
O'Donnell, Elizabeth K.
Sperling, Adam S.
Hartley-Brown, Monique A.
Midha, Shonali
Marto, Marjorie
Davie, Christine
Ricciardi, Caroline
Choden, Dechen
Strutevant, Ashlee
Alberti, Jillian
Trippa, Lorenzo
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul G.
Ghobrial, Irene M.
BLOOD, 2023, 142
[2] B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Nadeem, Omar
Redd, Robert A.
Prescott, Julia
Metivier, Amada
Tague, Kelsey
Romines, Veronica
Bertoni, Meredith
Savell, Alexandra
Medina, Rebekah
Distaso, Alexandra
Leblebjian, Houry
Mo, Clifton C.
Laubach, Jacob P.
Sperling, Adam S.
Richardson, Paul G.
Ghobrial, Irene M.
BLOOD, 2021, 138
[3] B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
Nadeem, Omar
Redd, Robert
Mo, Clifton Craig
Laubach, Jacob
Prescott, Julia
Metivier, Amada
Davie, Christine
Bertoni, Meredith
Murphy, Elizabeth
Sheehan, Brian
Tague, Kelsey
Shrestha, Hira
Medina, Rebekah
Distaso, Alexandra
Leblebjian, Houry
Richardson, Paul G.
Ghobrial, Irene M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Ghobrial, Irene M.
Badros, Ashraf Z.
Vredenburgh, James J.
Matous, Jeffrey
Caola, Aaron M.
Savell, Alexandra
Henrick, Patrick
Paba-Prada, Claudia E.
Schlossman, Robert L.
Laubach, Jacob P.
Rosenblatt, Jacalyn
Yee, Andrew
Wisch, Jeffrey S.
Farber, Charles M.
Maegawa, Rodrigo O.
Usmani, Saad Z.
Cappuccio, Joseph
Rivotto, Bradley
Noonan, Kimberly
Reyes, Kaitlen
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul
BLOOD, 2016, 128 (22)
[5] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Liu, Chia-Jen
Ghobrial, Irene M.
Bustoros, Mark
Reyes, Kaitlen
Hornburg, Kalvis
Badros, Ashraf Z.
Vredenburgh, James J.
Boruchov, Adam
Matous, Jeffrey V.
Caola, Aaron
Rivotto, Bradley
Savell, Alexandra
Henrick, Patrick
Paba-Prada, Claudia E.
Schlossman, Robert L.
Laubach, Jacob
Rosenblatt, Jacalyn
Yee, Andrew J.
Nadeem, Omar
Maegawa, Rodrigo O.
Jakubowiak, Andrzej
Usmani, Saad Z.
Bhutani, Manisha
Cappuccio, Joseph
Berrios, Brianna
Noonan, Kimberly
Zavidij, Oksana
Mouhieddine, Tarek H.
Boehner, Cody J.
Neuse, Carl-Jannes
Salem, Karma Ziad
Reidy, Mairead
Park, Jihye
Agius, Michael
Rahmat, Mahshid
Manier, Salomon
Bhutani, Divaya
Zonder, Jeffrey A.
Munshi, Nikhil
Auclair, Daniel
Anderson, Kenneth
Richardson, Paul
BLOOD, 2018, 132
[6] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Bustoros, Mark
Liu, Chia-jen
Reyes, Kaitlen
Hornburg, Kalvis
Guimond, Kathleen
Styles, Rachel
Savell, Alexandra
Berrios, Brianna
Warren, Diane
Dumke, Henry
Rivotto, Bradley
Henrick, Patrick
Scranton, Emily
Leblebjian, Houry
Meid, Kirsten
Schlossman, Robert L.
Munshi, Nikhil
Laubach, Jacob
Anderson, Kenneth C.
Richardson, Paul
Ghobrial, Irene M.
BLOOD, 2018, 132
[7] A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Nadeem, Omar
Reed, Robert A.
Prescott, Julia
Tague, Kelsey
Romines, Veronica
Metivier, Amada
Savell, Alexandra
Leblebjian, Houry
Distaso, Alexandra
Mo, Clifton C.
Laubach, Jacob P.
Sperling, Adam S.
Richardson, Paul G.
Ghobrial, Irene M.
BLOOD, 2021, 138
[8] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Bustoros, Mark
Nadeem, Omar
Sperling, Adam S.
Bianchi, Giada
Ardente, Lily
Redd, Robert A.
Prescott, Julia
Frey, Erin
Guimond, Kathleen
Styles, Rachel
Hornburg, Kalvis
Savell, Alexandra
Su, Nang Kham
Bindra, Govind
Boehner, Cody J.
Reyes, Kaitlen
Leblebjian, Houry
Warren, Diane
Munshi, Nikhil C.
Laubach, Jacob P.
Anderson, Kenneth C.
Richardson, Paul G.
Ghobrial, Irene M.
BLOOD, 2019, 134
[9] PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Ghobrial, I.
Caola, A.
Henrick, P.
Savell, A.
Cappuccio, J.
Rivotto, B.
Reyes, K.
Paba-Prada, C.
Schlossman, R.
Laubach, J.
Richardson, P.
Noonan, K.
Munshi, N.
Liu, C-J.
Bustoros, M.
Badros, A.
Matous, J.
Rosenblatt, J.
Yee, A.
Maegawa, R.
Usmani, S.
Vredenburgh, J.
Boruchov, A.
Nadeem, O.
Bhutani, D.
Jakubowiak, A.
Bhutani, M.
Salem, K.
Manier, S.
Park, J.
HAEMATOLOGICA, 2017, 102 : 317 - 317
[10] Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, Maria-Victoria
Hernandez, Miguel-Teodoro
Giraldo, Pilar
de la Rubia, Javier
de Arriba, Felipe
Lopez Corral, Lucia
Rosinol, Laura
Paiva, Bruno
Palomera, Luis
Bargay, Joan
Oriol, Albert
Prosper, Felipe
Lopez, Javier
Olavarria, Eduardo
Quintana, Nuria
Garcia, Jose-Luis
Blade, Joan
Lahuerta, Juan-Jose
San Miguel, Jesus-F.
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (05): : 438 - 447

← 1 2 3 4 5 →